Results 31 to 40 of about 957 (170)

Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus

mBio, 2023
Mycobacterium abscessus (Mab) affects patients with immunosuppression or underlying structural lung diseases such as cystic fibrosis (CF). Additionally, Mab poses clinical challenges due to its resistance to multiple antibiotics.
Khalid M. Dousa, Eunjeong Shin, Sebastian G. Kurz, Mark Plummer, Mary Nantongo, Christopher R. Bethel, Magdalena A. Taracila, David C. Nguyen, Barry N. Kreiswith, Charles L. Daley, Kenneth E. Remy, Steven M. Holland, Robert A. Bonomo   +12 more
doaj   +4 more sources

Therapeutic challenges and emerging strategies against carbapenem-resistant Acinetobacter baumannii [PDF]

Current Research in Microbial Sciences
Carbapenem-resistant Acinetobacter baumannii (CRAB) remains a formidable clinical challenge, driven by limited therapeutic options and multifaceted resistance mechanisms.
Chunhong Yang, Jing Li, Xiao Luo, Zhangyong Song, Jinping Zhang   +4 more
doaj   +2 more sources

From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem? [PDF]

Curr Opin Infect Dis
Purpose of review Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections.
Bonazzetti C, Giannella M, Pascale R.
europepmc   +6 more sources

Multidrug-Resistant Acinetobacter baumannii: Resistance Mechanisms, Emerging Therapies, and Prevention—A Narrative Review

Antibiotics
Acinetobacter baumannii is a leading intensive care unit (ICU) pathogen associated with high rates of carbapenem resistance and poor clinical outcomes.
Ioana Adelina Stoian, Bianca Balas Maftei, Carmen-Elena Florea, Alexandra Rotaru, Constantin Aleodor Costin, Maria Antoanela Pasare, Radu Crisan Dabija, Carmen Manciuc   +7 more
doaj   +2 more sources

Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against Mycobacterium abscessus

Microbiology Spectrum
Despite the long therapy duration, the treatment outcomes for Mycobacterium abscessus lung disease (MAB-LD) are very poor. β-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB β-lactamase ...
Avneesh Shrivastava, Gunavanthi D. Boorgula, Sanjay Singh, Danaleigh Stiles, Pamela J. McShane, Megan Devine, Tawanda Gumbo, Shashikant Srivastava   +7 more
doaj   +3 more sources

A randomized, double‐blind, placebo‐ and positive‐controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Clinical and Translational Science, 2021
Durlobactam (formerly ETX2514) is a diazabicyclooctane β‐lactamase inhibitor that inhibits class A, C, and D β‐lactamases. Sulbactam combined with durlobactam has in vitro and in vivo activity against Acinetobacter baumannii including carbapenem‐ and ...
John O’Donnell, Kathleen Maloney, Melissa Steidler, Royce Morrison, Robin Isaacs   +4 more
doaj   +1 more source

In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates. [PDF]

J Antimicrob Chemother
Objectives: To evaluate the in vitro activity of cefepime in association with a β-lactamase inhibitor (enmetazobactam) or β-lactam enhancer (BLE), zidebactam, against carbapenem-resistant Acinetobacter baumannii (CRAB) strains susceptible or resistant to
Tascini C, Bianco G, Bonomo RA, Gaibani P.   +3 more
europepmc   +2 more sources

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors

Antibiotics, 2021
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci, Francesca Mattioli, Marco Falcone, Antonello Di Paolo   +3 more
doaj   +1 more source

Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action

mBio, 2022
Mycobacterium abscessus (Mab) infections are a growing menace to the health of many patients, especially those suffering from structural lung disease and cystic fibrosis.
Khalid M. Dousa, David C. Nguyen, Sebastian G. Kurz, Magdalena A. Taracila, Christopher R. Bethel, William Schinabeck, Barry N. Kreiswirth, Sheldon T. Brown, W. Henry Boom, Richard S. Hotchkiss, Kenneth E. Remy, Frank J. Jacono, Charles L. Daley, Steven M. Holland, Alita A. Miller, Robert A. Bonomo   +15 more
doaj   +1 more source

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumannii

Antimicrobial Agents and Chemotherapy, 2023
ABSTRACTAcinetobacter baumannii-calcoaceticuscomplex (ABC) causes severe infections that are difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat serious infections caused byAcinetobacter, including multidrug- and carbapenem ...
Samir H. Moussa, Adam B. Shapiro, Sarah M. McLeod, Ramkumar Iyer, Nicole M. Carter, Yu-Kuo Tsai, L. Kristopher Siu, Alita A. Miller   +7 more
openaire   +2 more sources